Efficacy of Ramosetron on Irritable Bowel Syndrome - like Symptoms in Patients with Inactive Inflammatory Bowel Disease - A Randomized, Double-blind, Placebo-Controlled Study -

Efficacy of Ramosetron on Irritable Bowel Syndrome - like Symptoms in Patients with Inactive Inflammatory Bowel Disease - A Randomized, Double-blind, Placebo-Controlled Study - - Efficacy of Ramosetron on Irritable Bowel Syndrome - like Symptoms in Patients with Inactive Inflammatory Bowel Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023399

Enrollment

Registered

2016-07-30

Start date

2016-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inactive Inflammatory bowel disease with Irritable bowel syndrome-like symptoms diadnosed by Rome III criteria

Interventions

Ramosetron Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Inactive IBD patients with diarrhea predominant IBS-like symptom diagnosed according to the Rome III criteria. 2)The remission stage of IBD was defined as follows. CD: Crohn's disease activity Index index under 150, UC: clinical activity index for the evaluation of patients with ulcerative colitis index under 4 and CRP under 0.3. 3)They had type 6 or 7 stool form, as scored by BSFS, recorded during the baseline period; had bowel movements 2 days or more per week. 4)Organic diseases were excluded by total colonoscopy or double-contrast barium enema.These examinations had to have been performed within 2 years before the provisional registration of subjects and after the onset of IBS symptoms. 5)They recorded all items in the patient diary for 5 days or more during the baseline period.

Exclusion criteria

Exclusion criteria: Candidates were excluded from participation if they had a history of abdominal surgery, had serious infectious colitis, had a history of ischemic colitis, had ischemic colitis.

Design outcomes

Primary

Measure	Time frame
Monthly responder rates of global assessment of relief of overall IBS symptoms,	—

Countries

Japan

Contacts

Public ContactToshihiko Tomita

Dr. Division of Gastroenterology, Department of Internal Medicine

tomita@hyo-med.ac.jp0798456661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026